These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17448593)

  • 1. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
    Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
    Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
    Prayer-Galetti T
    Eur Urol; 2007 Oct; 52(4):1087-8. PubMed ID: 17448594
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
    Maier C
    Eur Urol; 2007 Oct; 52(4):1088-9. PubMed ID: 17448591
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
    Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
    Jaffe JM; Malkowicz SB; Walker AH; MacBride S; Peschel R; Tomaszewski J; Van Arsdalen K; Wein AJ; Rebbeck TR
    Cancer Res; 2000 Mar; 60(6):1626-30. PubMed ID: 10749132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
    Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
    Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
    van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
    Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP
    Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
    Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
    Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
    Scorilas A; Bharaj B; Giai M; Diamandis EP
    Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.
    Makridakis N; Akalu A; Reichardt JK
    Oncogene; 2004 Sep; 23(44):7399-405. PubMed ID: 15326487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.